Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC (vol 4, pg 860, 2023)Caicun Zhou,Ziping Wang,Meili Sun,Lejie Cao,Zhiyong Ma,Rong Wu,Yan Yu,Wenxiu Yao,Si Sun,Jianhua Chen,Wu Zhuang,Jiuwei Cui,Xueqin Chen,You Lu,Hong Shen,Chunhong Hu,Jiwei Liu,Yunpeng Liu,Mengzhao Wang,Xingya Li,Ping Sun,Yongqian Shu,Jianying Zhou,Jingzhang Li,Kangsheng Gu,Changli Wang,Hui Zhao,Yiping Zhang,Chunling Liu,Jingru Wang,Rumei Chen,Mengmeng Qin,Hao Wang,Jason YangNATURE CANCER（2024）引用 0|浏览9暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
